0.02Open0.02Pre Close0 Volume1.44K Open Interest8.00Strike Price0.00Turnover2402.55%IV39.24%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.02Time Value100Contract SizeAmericanOptions Type0.0479Delta0.0927Gamma288.00Leverage Ratio-2.2981Theta0.0000Rho13.80Eff Leverage0.0000Vega
Aurinia Pharmaceuticals Stock Discussion
NEWS
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024
Aurinia Pharmaceuticals (NASDAQ: AUPH) announced the cost-effectiveness of LUPKYNIS® (voclosporin) for treating lupus nephritis (LN) at the National Kidney Foundation Spring Clinical Meeting 2024. The updated analysis, consistent with a 2021 assessment, utilized the ICER AnalyticsTM LN model and found LUPKYNIS ...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US)$
NEWS
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required af...
No comment yet